金吾财讯 | Prime Medicine（PRME）盘前涨10.45%，报3.391美元。消息面上，美国食品药品监督管理局（FDA）批准其PM647的新药临床试验申请（IND）。获批使Prime Medicine能够启动一项评估PM647用于患有该遗传性疾病成人患者的1/2期试验。预计将于2027年获得初步临床数据。PM647是一种用于治疗α-1抗胰蛋白酶缺乏症的实验性基因编辑疗法。PM647旨在修复导致α-1抗胰蛋白酶缺乏症的基因突变。
金吾财讯 | Prime Medicine（PRME）盘前涨10.45%，报3.391美元。消息面上，美国食品药品监督管理局（FDA）批准其PM647的新药临床试验申请（IND）。获批使Prime Medicine能够启动一项评估PM647用于患有该遗传性疾病成人患者的1/2期试验。预计将于2027年获得初步临床数据。PM647是一种用于治疗α-1抗胰蛋白酶缺乏症的实验性基因编辑疗法。PM647旨在修复导致α-1抗胰蛋白酶缺乏症的基因突变。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.